Johnson & Johnson (NYSE:JNJ) Stock Position Raised by Headlands Technologies LLC

Key Points

• Headlands Technologies LLC increased its stake in Johnson & Johnson by 82.2% during the first quarter, owning 31,135 shares worth approximately $5.16 million.
• Johnson & Johnson reported a quarterly EPS of $2.77, surpassing analysts' expectations of $2.68, with revenues reaching $23.74 billion—up 5.8% year-over-year.
• The company recently announced a quarterly dividend of $1.30 per share, providing an annualized yield of 3.0%; the dividend payout ratio stands at 55.61%.

Headlands Technologies LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 82.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 31,135 shares of the company's stock after purchasing an additional 14,051 shares during the period. Headlands Technologies LLC's holdings in Johnson & Johnson were worth $5,163,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Elios Financial Group Inc. boosted its holdings in Johnson & Johnson by 1.5% in the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after purchasing an additional 66 shares during the last quarter. Atlantic Family Wealth LLC lifted its holdings in Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after buying an additional 67 shares during the last quarter. MBA Advisors LLC lifted its holdings in Johnson & Johnson by 1.2% during the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after buying an additional 68 shares during the last quarter. Sovereign Financial Group Inc. lifted its holdings in Johnson & Johnson by 1.8% during the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after buying an additional 69 shares during the last quarter. Finally, Nabity Jensen Investment Management Inc lifted its holdings in Johnson & Johnson by 1.5% during the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after buying an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on JNJ shares. UBS Group increased their target price on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Price Performance

Shares of JNJ stock traded up $1.87 during mid-day trading on Friday, hitting $173.40. 7,686,049 shares of the stock traded hands, compared to its average volume of 9,496,232. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $173.96. The firm has a market cap of $417.61 billion, a price-to-earnings ratio of 18.55, a price-to-earnings-growth ratio of 2.21 and a beta of 0.41. The company's 50-day simple moving average is $159.26 and its 200-day simple moving average is $157.52. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period last year, the firm earned $2.82 EPS. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.